Pivotal Therapeutics Inc. is a specialty pharmaceutical company with a focus on optimizing Omega-3 therapy for cardiovascular disease and overall health. Pivotal developed its lead product VASCAZEN® based on the scientific evidence on the benefits of Omega-3 for cardiovascular patients. VASCAZEN® is currently available in the U.S. as a prescription only medical food specifically formulated for the dietary management of Omega-3 Deficiency (OM3D) in patients with cardiovascular disease (CVD). VASCAZEN® is a >90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid formulation protected by a series of both U.S. and foreign patents.
VASCAZEN® has been clinically shown to correct an Omega-3 Deficiency within eight weeks of treatment with positive concomitant effects on the lipid profiles, mainly a 48% reduction of triglycerides and an increase in HDL-C without a negative impact on the LDL-C lipid profile. VASCAZEN® results were achieved with a dose of three grams of EPA and DHA per day of a prescription grade, high purity Omega-3 formulation.
Pivotal’s second product, OMAZEN® is a greater than 90% pure, pharmaceutical grade Omega-3 commercialized for sale and distribution in Canada only for the maintenance of good health. The unique formulation and dosage is available for sale to consumers who realize the health benefits of high purity Omega-3 supplementation.